Myriad Genetics Inc
Company Profile
Business description
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Contact
322 North 2200 West
Salt Lake CityUT84116
USAT: +1 801 584-3600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,700
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,812.70 | 70.80 | 0.81% |
| CAC 40 | 7,804.33 | 12.86 | 0.17% |
| DAX 40 | 23,987.56 | 186.76 | -0.77% |
| Dow JONES (US) | 42,866.87 | 105.11 | 0.25% |
| FTSE 100 | 8,853.08 | 20.80 | 0.24% |
| HKSE | 24,162.87 | 18.56 | -0.08% |
| NASDAQ | 19,714.99 | 123.75 | 0.63% |
| Nikkei 225 | 38,211.51 | 122.94 | 0.32% |
| NZX 50 Index | 12,564.42 | 25.16 | 0.20% |
| S&P 500 | 6,038.81 | 32.93 | 0.55% |
| S&P/ASX 200 | 8,587.20 | 71.50 | 0.84% |
| SSE Composite Index | 3,384.82 | 14.96 | -0.44% |